Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Vividion Therapeutics, Inc.
Seagen Inc.
Novartis
Hoffmann-La Roche
M.D. Anderson Cancer Center
EMD Serono
Pfizer
Pfizer
AstraZeneca
Genentech, Inc.
Eli Lilly and Company
Peking University Cancer Hospital & Institute
GlaxoSmithKline
Pfizer
AbbVie
University of Alabama at Birmingham
Toray Industries, Inc
City of Hope Medical Center
Shanghai Junshi Bioscience Co., Ltd.
Inspirna, Inc.
IGM Biosciences, Inc.
Ohio State University Comprehensive Cancer Center
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hansoh BioMedical R&D Company
Ohio State University Comprehensive Cancer Center
MEI Pharma, Inc.
Pfizer
Taiho Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co. Ltd
Servier
Tesaro, Inc.
Shanghai Zhongshan Hospital
Lebanese University
SCRI Development Innovations, LLC
Genentech, Inc.
AbbVie
Sumitomo Pharma Co., Ltd.
Shandong Boan Biotechnology Co., Ltd
Novartis
Fujian Cancer Hospital
Gilead Sciences
TG Therapeutics, Inc.
Hoffmann-La Roche
mAbxience Research S.L.
University of Chicago
Lipomedix Pharmaceuticals Inc.
Genentech, Inc.